Publications by authors named "M Macro"

Claim this Profile
S
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot, Margaret Macro

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, Denis Caillot, Arthur Bobin, Margaret Macro

Clin Hematol Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, Titouan Cazaubiel, Marie-Lorraine Chretien, Margaret Macro

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.
Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, Denis Caillot, Arthur Bobin, Margaret Macro

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis